Predictive and Prognostic Utility of the Serum Level of Resistin-Like Molecule Beta for Risk Stratification in Patients with Community-Acquired Pneumonia

Abstract

Despite progress in intensive care, the morbidity and mortality of patients with community-acquired pneumonia (CAP) remains high. Furthermore, the predictive and prognostic utility of resistin-like molecule beta (RELM-β) in patients with CAP is uncertain. This study investigated the role of RELM-β in patients with CAP and evaluated its correlation with disease severity and the risk of death. A prospective, multicenter study was conducted in 2017, and admission serum levels of RELM-β were detected using quantitative enzyme-linked immunosorbent assay. A total of 114 and 112 patients with severe CAP (SCAP) and non-severe CAP (NSCAP) were enrolled, respectively, with 15 healthy controls. Patients with SCAP, especially non-survivors, had significantly higher levels of serum RELM-β than patients with NSCAP. RELM-β levels positively correlated with severity scores and consistently predicted SCAP in patients with CAP (area under the curve = 0.794). Increased levels of RELM-β were closely related to the severity and prognosis of patients with CAP. The accuracy of 30-day mortality predictions of CURB-65 (confusion, urea, respiratory rate, blood pressure, and age ≥ 65 years) can be significantly improved when combined with RELM-β levels. The level of RELM-β can assist clinicians in risk stratification of patients with CAP in early stages.

Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases

“…Elevated levels of RELMβ are closely related to the severity and prognosis of disease in patients with community-acquired pneumonia (CAP) [ 96 ]. Serum RELMβ levels are significantly increased in patients with severe CAP, particularly in non-survivors [ 96 ].…”

“…Elevated levels of RELMβ are closely related to the severity and prognosis of disease in patients with community-acquired pneumonia (CAP) [ 96 ]. Serum RELMβ levels are significantly increased in patients with severe CAP, particularly in non-survivors [ 96 ]. Meanwhile, the serum RELMβ level in patients with bacterial infection is notably higher than that in patients with non-bacterial infection [ 96 ].…”

“…Serum RELMβ levels are significantly increased in patients with severe CAP, particularly in non-survivors [ 96 ]. Meanwhile, the serum RELMβ level in patients with bacterial infection is notably higher than that in patients with non-bacterial infection [ 96 ]. However, the RELMβ level in the Mycoplasma pneumonia -positive group is significantly lower than that in the Mycoplasma pneumonia -negative group [ 96 ].…”

“…Meanwhile, the serum RELMβ level in patients with bacterial infection is notably higher than that in patients with non-bacterial infection [ 96 ]. However, the RELMβ level in the Mycoplasma pneumonia -positive group is significantly lower than that in the Mycoplasma pneumonia -negative group [ 96 ]. Elevated levels of RELMβ displays positive correlations with the pneumonia severity index (PSI) and CURB-65 [ 96 ].…”

“…However, the RELMβ level in the Mycoplasma pneumonia -positive group is significantly lower than that in the Mycoplasma pneumonia -negative group [ 96 ]. Elevated levels of RELMβ displays positive correlations with the pneumonia severity index (PSI) and CURB-65 [ 96 ]. RELMβ in serum of patients with CAP is associated with 30-day mortality outcome; and the combination of clinical severity score and RELMβ significantly improve mortality predictive ability [ 96 ].…”